Immunomedics (NASDAQ:IMMU) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
IMMU has been the subject of a number of other research reports. BidaskClub upgraded Immunomedics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 25th. TheStreet upgraded Immunomedics from a “d” rating to a “c-” rating in a report on Friday, February 9th. Jefferies Group increased their target price on Immunomedics from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Finally, Zacks Investment Research cut Immunomedics from a “hold” rating to a “sell” rating in a report on Saturday, February 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $19.00.
IMMU stock traded up $1.10 during trading hours on Thursday, reaching $16.92. 2,821,808 shares of the stock were exchanged, compared to its average volume of 2,239,771. The stock has a market cap of $2,533.02, a PE ratio of -20.89 and a beta of 1.62. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.20. Immunomedics has a 12 month low of $5.00 and a 12 month high of $18.93.
In other news, Director David M. Goldenberg sold 17,729 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $17.09, for a total value of $302,988.61. Following the completion of the transaction, the director now owns 1,774,285 shares in the company, valued at approximately $30,322,530.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David M. Goldenberg sold 40,000 shares of the firm’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $17.24, for a total value of $689,600.00. Following the completion of the transaction, the director now owns 1,774,285 shares of the company’s stock, valued at approximately $30,588,673.40. The disclosure for this sale can be found here. Insiders sold a total of 77,729 shares of company stock valued at $1,342,589 in the last 90 days. 14.80% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Calton & Associates Inc. bought a new position in shares of Immunomedics in the 4th quarter valued at about $135,000. Xact Kapitalforvaltning AB bought a new position in shares of Immunomedics in the 4th quarter valued at about $193,000. Sapphire Star Partners LP bought a new position in shares of Immunomedics in the 4th quarter valued at about $323,000. SG Americas Securities LLC grew its holdings in shares of Immunomedics by 27.2% in the 3rd quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock valued at $368,000 after acquiring an additional 5,631 shares in the last quarter. Finally, Virtus Fund Advisers LLC bought a new position in shares of Immunomedics in the 4th quarter valued at about $456,000. Institutional investors own 74.51% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://dakotafinancialnews.com/2018/04/13/immunomedics-immu-upgraded-to-buy-at-valuengine.html.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.